• Rotenone and Mitochondrial Complex I: Strategic Pathways for

  2026-05-21

  This article explores how Rotenone, a benchmark mitochondrial Complex I inhibitor, empowers translational researchers to interrogate mitochondrial dysfunction, apoptosis, and autophagy. Integrating mechanistic insights from recent discoveries about TCAIM-mediated metabolic regulation, we provide actionable guidance on experimental design, highlight competitive research strategies, and offer a future-facing perspective on disease modeling and therapeutic innovation.

• Decitabine (5-Aza-2'-deoxycytidine): Protocols and Innovatio

  2026-05-20

  Decitabine (5-Aza-2'-deoxycytidine) is revolutionizing both hematopoietic malignancy and solid tumor epigenetic studies by enabling precise DNA demethylation and tumor suppressor gene reactivation. This article details actionable workflows, advanced experimental use-cases, and troubleshooting insights—empowering cancer epigenetics researchers to maximize data quality and biological impact with APExBIO’s trusted formulation.

• M344 HDAC Inhibitor Suppresses Neuroblastoma Growth In Vivo

  2026-05-20

  The referenced study demonstrates that the histone deacetylase inhibitor M344 robustly suppresses tumor growth and alters malignant phenotypes in neuroblastoma models. Its superior cytostatic, cytotoxic, and migration-inhibitory effects compared to established agents highlight M344’s promise for advancing pediatric cancer research and therapy.

• Belinostat (PXD101): Precision HDAC Inhibition in Cancer Res

  2026-05-19

  Belinostat (PXD101) is redefining epigenetic cancer research with nanomolar potency and highly reproducible HDAC inhibition. This article bridges bench workflows with advanced troubleshooting to maximize performance in bladder and prostate cancer models.

• Nirmatrelvir (PF-07321332) Advances SARS-CoV-2 Inhibition Re

  2026-05-19

  Nirmatrelvir (PF-07321332) empowers researchers to dissect and disrupt SARS-CoV-2 replication by selectively targeting 3CL protease. This guide delivers optimized workflows, troubleshooting insights, and context from in silico discovery to wet-lab protocol design, highlighting APExBIO’s commitment to rigor and reproducibility.

• I-BET-762: BET Inhibitor Workflows in Inflammation and Cance

  2026-05-18

  I-BET-762 is a selective BET inhibitor that enables precision control of transcriptional programs in cancer and inflammation models. This article dissects experimental strategies, protocol enhancements, and troubleshooting tactics based on the latest mechanistic evidence, illuminating how I-BET-762 accelerates research on ferroptosis and LPS-driven gene expression.

• Primidone (Mysoline): Dual Inhibitor of TRPM3 and RIPK1 in A

  2026-05-18

  Primidone (Mysoline) is a clinically established antiepileptic and anti-tremor drug that also acts as a dual inhibitor of TRPM3 cation channels and RIPK1 kinase. Recent evidence demonstrates its capacity to reduce peripheral biomarkers and delay symptom onset in amyotrophic lateral sclerosis (ALS) models. Its mechanistic selectivity and protocol parameters are well-characterized for translational neurodegeneration research.

• Phase Separation and Plant Virus Movement: Insights from PEM

  2026-05-17

  Brown et al. (2021) demonstrate that the movement protein p26 from Pea enation mosaic virus 2 (PEMV2) undergoes phase separation with key cellular factors, facilitating virus-host interactions critical for systemic infection. This work reveals how electrostatic interactions drive the formation of membraneless compartments, advancing our understanding of plant virus trafficking and offering new molecular tools for dissecting RNA–protein assemblies.

• hCG Regulates CXCL10 via Histone Methylation in Human Decidu

  2026-05-16

  This study uncovers how human chorionic gonadotropin (hCG) suppresses CXCL10 expression in human decidua by promoting H3K27 trimethylation at its promoter, mediated by EZH2. These findings clarify a key epigenetic mechanism regulating immune cell recruitment at the maternal-fetal interface, with implications for reproductive immunology and inflammatory disorder research.

• GSK343 and EZH2 Inhibition: Epigenetic Leverage for Translat

  2026-05-15

  This article explores the mechanistic underpinnings and translational opportunities of GSK343, a potent and selective EZH2 inhibitor, in the context of cancer immunogenicity and epigenetic reprogramming. Integrating recent discoveries around PRC2, H3K27 methylation, and CBX2-mediated immune evasion, we provide strategic guidance for researchers seeking to harness GSK343’s unique attributes in precision epigenetic oncology. We contrast GSK343’s performance with other tool compounds, address workflow optimization, and map out the future of epigenetic modulation for immunotherapy.

• BRD4770: Reliable G9a Inhibition for Robust Epigenetic Assay

  2026-05-15

  Laboratory reproducibility in epigenetic and cell proliferation assays hinges on both molecular specificity and product integrity. BRD4770 (SKU B4837) enables precise inhibition of G9a histone methyltransferase, supporting bench scientists with validated workflows and data-backed reliability. This scenario-driven guide details best practices and critical decision points for leveraging BRD4770 in advanced cancer biology research.

• NAD+/NADH Balance in Fungal Hypoxia: Metabolic Adaptation Me

  2026-05-14

  This review dissects how NAD+/NADH homeostasis underpins metabolic adaptation to hypoxia and secondary metabolite production in filamentous fungi. By detailing redox-triggered pathway shifts and regulatory mechanisms, the study illuminates fundamental processes relevant to bioindustrial fermentation, disease modeling, and mitochondrial research.

• Harnessing Cefoperazone Sodium Salt in Antimicrobial Assays

  2026-05-14

  Cefoperazone sodium salt stands out in antimicrobial research for its robust β-lactamase stability and proven broad-spectrum efficacy. This article delivers actionable workflows, troubleshooting guidance, and comparative insights—empowering researchers to optimize in vitro antibacterial activity assays and resistance studies with confidence.

• HyperFluor™ 594 Goat Anti-Rabbit IgG: Specificity & Protocol

  2026-05-13

  The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody is an affinity-purified, fluorophore-conjugated secondary antibody from APExBIO. It enables sensitive, multiplexed detection of rabbit IgG in immunocytochemistry, IHC, and flow cytometry, with strict protocol parameters for optimal signal and specificity. This dossier details its mechanism, benchmarks, and practical integration in advanced research workflows.

• EPZ5676: Transforming DOT1L Inhibitor Workflows in Leukemia

  2026-05-13

  EPZ5676, a highly selective DOT1L inhibitor, empowers researchers to dissect H3K79 methylation with unmatched precision. This guide delivers practical workflow strategies, troubleshooting insights, and comparative advantages for MLL-rearranged leukemia studies.

7969 records 13/532 page Previous Next First page 上5页 1112131415 下5页 Last page